NASDAQ
QNTM
Last Price
US $3.49
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Quantum BioPharma Ltd. cash flow to debt ratio of -447.52% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Quantum BioPharma Ltd.'s free cash flow has decreased 21.88% from $-6.88M last year to $-8.38M, signaling decreasing performance
Financial risk - Healthy debt to equity ratio.
Quantum BioPharma Ltd.'s debt to equity ratio is 1.46, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy
Financial risk - Healthy debt to equity ratio development.
Quantum BioPharma Ltd.'s debt has increased relative to shareholder equity from 0.07 last year to 1.46 today, signaling weakened financials
Financial risk - Net debt/EBITDA.
Quantum BioPharma Ltd. has negative EBITDA, making leverage ratio unreliable
Financial risk - ICR.
Quantum BioPharma Ltd.'s interest coverage ratio is -11.73, which means that the company struggles to meet interest obligations, signaling financial risk.
Financial risk - Profit margin growth.
Quantum BioPharma Ltd. has insufficient data to evaluate this check.
Financial stability - Short term assets vs short term liabilities.
Quantum BioPharma Ltd.'s short-term assets of $6.47M exceed its short-term liabilities of $6.05M
Decreasing performance - ROA.
Quantum BioPharma Ltd.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Quantum BioPharma Ltd.'s return on equity of -621.76%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Quantum BioPharma Ltd.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Quantum BioPharma Ltd. had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Quantum BioPharma Ltd. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Quantum BioPharma Ltd. has negative free cash flow, indicating cash burn
Decreasing performance - Healthy earnings growth.
Quantum BioPharma Ltd.'s yearly earnings has decreased 84.30% since last year from $-14.20M to $-26.18M, signaling decreasing performance
Increasing performance - Healthy revenue growth.
Quantum BioPharma Ltd.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance
Increasing performance - ROIC.
ROIC 819.14% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.
Decreasing performance - 3-year revenue CAGR.
Quantum BioPharma Ltd. has insufficient revenue history to calculate 3-year revenue CAGR.
Increasing performance - Revenue consistency.
Quantum BioPharma Ltd. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Quantum BioPharma Ltd. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Quantum BioPharma Ltd. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Quantum BioPharma Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Quantum BioPharma Ltd. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Quantum BioPharma Ltd. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Quantum BioPharma Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - P/B ratio.
Quantum BioPharma Ltd. has negative shareholder equity; price-to-book is not meaningful and the check fails
Overvalued - P/S ratio.
Quantum BioPharma Ltd. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-621.76%
Return on equity
ROIC: 819.14%
Valuation History
-0.40X
Price to Earnings
EV/EBITDA: -0.37X
Cash flow
Profit margin
-1.17%
(FY vs FY)
Cash flow Y/Y
17.95%
(FY vs FY)
Fair Value
Market $3.49
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.